Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
10 participants
INTERVENTIONAL
2018-12-01
2022-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Burst Spinal Cord Stimulation (Burst-SCS) Study
NCT03718325
Efficacy of Spinal Cord Stimulation in Patients With a Failed Back Surgery Syndrome.
NCT03462147
Mechanisms and Outcome-Prognostication for Paresthesia-based and -Free Spinal Cord Stimulation
NCT03852381
Effectiveness of Precision Spinal Cord Stimulation With Artisan Paddle Electrode
NCT00386724
A Novel Approach in Spinal Cord Stimulation: a Combination of Burst and Tonic Waveforms.
NCT03201705
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The participants whose pain remains stable while on the LAP will be categorized as Group 2. All participants will keep a daily diary for pain intensity, sleep and any other concerns that may arise related to the change of program.
At the end of Visit 1, a member of the study team will schedule Visit 2, between 14 to 28 days from Visit 1.
Phone call: A study physician will call subjects between 7-14 days after Visit 1. Group 1 participants will be asked to switch to the LAP (P2 or P3) before Visit 2. To minimize the duration of the LAP, Visit 2 will be scheduled within six hours from the end of COT. The Group 2 participants will attend Visit 2 without changing their LAP.
At Visit 2, participants will fill out questionnaires on pain intensity, sleep, activities and global impression. A blinded study staff will perform QST on the subject. At the end of Visit 2, Group 1 participants will be instructed to go back to the OPP (P1). At the end of Visit 2, Group 2 will be allowed to switch back to the OPP (P1).
The investigators will use quantitative sensory testing (QST) as a tool to objectively quantify the impact of SCS on heat pain threshold, heat pain tolerance and wind-up over the painful area and compare this with a non-painful area in each subject. QST will be performed at Visit 1 and Visit 2.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pain Returns
PF-SCS programming: in a blinded fashion, subjects will be asked to switch to the lowest amplitude program (LAP). Subjects whose pain returns after switching to the LAP will be considered Group 1.
PF-SCS programming
In a blinded fashion, the study physician will ask subjects to switch their PF-SCS to the LAP.
No Pain
PF-SCS programming: in a blinded fashion, subjects will be asked to switch to the lowest amplitude program (LAP). Subjects whose pain does not return after switching to the LAP will be considered Group 2.
PF-SCS programming
In a blinded fashion, the study physician will ask subjects to switch their PF-SCS to the LAP.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-SCS programming
In a blinded fashion, the study physician will ask subjects to switch their PF-SCS to the LAP.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject who is currently treated with PF-SCS (HF-10 or Burst-mode capable SCS system) for chronic pain
Exclusion Criteria
* Those receiving remuneration for their pain treatment (pending litigation or ongoing litigation).
* Those unable to read English and complete the assessment instruments.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Massachusetts General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shihab Ahmed, MD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shihab Ahmed, M.D.
Role: PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MGH Center for Translational Pain Research
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018P-001645
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.